Simcere Beefs Up Sales Force, Carves Out Provincial Sales Strategy To Drive Growth In China
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI- U.S.-listed Simcere Pharmaceutical is expanding its sales force in China for future growth and recently received Chinese regulatory approval for palonosetron, a second-generation 5-HT3 antagonist for the prevention and control of acute chemotherapy-induced nausea and vomiting, the company announced during its most recent earnings call
You may also be interested in...
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
Merck, Simcere Form JV To Expand Access To Lifestyle Drugs Across China
SHANGHAI - Merck & Co. affiliate MSD signed an agreement to form a joint venture July 21 with Simcere Pharmaceutical Group that will see both companies expand access to critical lifestyle drugs across China
China's Simcere Looks To Move Past Vaccine Troubles, Focuses On New GMP Requirements, Partnering With Big Pharma
BEIJING - Leading Chinese drug maker Simcere Pharmaceutical Group, which develops innovative medicines, first-to-market generics and biosimilars, reported this week that its earnings for 2010 skyrocketed, despite its takeover of a vaccine producer that was slapped with substantial fines last year for turning out a "substandard rabies vaccine.